◎ Sugi Atlas

Atlas / Drug / Oxaliplatin

Oxaliplatin

drug
On this page

Also known as EloxatinJM-83L-OHPMBP-426 (LIPOSOMAL OXALIPLATIN)NSC-266046Oxaliplatin component of folfoxOxaliplatin component of xeloxOxaliplatineOxaliplatinoRP-54780SR-96669XaliplatinCis-Platinum (II) ConjugateSID144206138SID144206182

Summary

Oxaliplatin (CHEMBL414804) is an approved small molecule (ATC L01XA03); indicated across 104 conditions including neoplasm and colorectal adenocarcinoma; with CIViC clinical evidence for 19 variant-indication associations (e.g. BRCA1 Mutation in pancreatic cancer).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: L01XA03
  • Indications: 104 conditions
  • Clinical trials: 1,475
  • Precision-oncology evidence (CIViC): 19 variant–indication associations

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL414804
NameOxaliplatin
TypeSmall molecule
Max phase4
ATCL01XA03

Also known as: Eloxatin, JM-83, L-OHP, MBP-426 (LIPOSOMAL OXALIPLATIN), NSC-266046, Oxaliplatin, Oxaliplatin component of folfox, Oxaliplatin component of xelox, Oxaliplatine, Oxaliplatino, RP-54780, SR-96669

Parent form; salt/anhydrous children: CHEMBL1983570

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

33 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

IndicationPhaseMONDOEFO
neoplasm4MONDO:0005070EFO:0000616
colorectal adenocarcinoma3MONDO:0005008EFO:0000365
gastric neoplasm3MONDO:0021085EFO:0003897
gastric adenocarcinoma3MONDO:0005036EFO:0000503
hepatocellular carcinoma3MONDO:0007256EFO:0000182
carcinoma of esophagus3MONDO:0019086EFO:0002916
biliary tract neoplasm3MONDO:0005304EFO:0003891
non-Hodgkin lymphoma3MONDO:0018908EFO:0005952
gastric carcinoma3MONDO:0004950EFO:0000178
exocrine pancreatic carcinoma3MONDO:0005192EFO:0002618
squamous cell carcinoma3MONDO:0005096EFO:0000707
rectal cancer3MONDO:0006519EFO:1000657
adenocarcinoma3MONDO:0004970EFO:0000228
carcinoma3MONDO:0004993EFO:0000313
diffuse large B-cell lymphoma3MONDO:0018905EFO:0000403
lymphoma3MONDO:0005062EFO:0000574
non-small cell lung carcinoma3MONDO:0005233EFO:0003060
pancreatic neoplasm3MONDO:0021040EFO:0003860
colorectal neoplasm3MONDO:0005335EFO:0004142
colonic neoplasm3MONDO:0005401EFO:0004288
cholangiocarcinoma3MONDO:0019087EFO:0005221
colorectal carcinoma3MONDO:0024331EFO:1001951
gallbladder carcinoma3MONDO:0003220EFO:1001956
intrahepatic cholangiocarcinoma3MONDO:0003210EFO:1001961
esophageal squamous cell carcinoma3MONDO:0005580EFO:0005922
testicular cancer3MONDO:0005447EFO:0004281
hepatoblastoma3MONDO:0018666EFO:1000292
colon adenocarcinoma3MONDO:0002271EFO:1001949
gallbladder neoplasm3MONDO:0021253MONDO:0005411
rectal neoplasm3MONDO:0002165MONDO:0044937
malignant pancreatic neoplasm3MONDO:0009831EFO:1000359
colon carcinoma3MONDO:0002032EFO:1001950
pancreatic ductal adenocarcinoma3MONDO:0005184MONDO:0005184

48 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)PhaseMONDOEFO
teratoma3MONDO:0002601MONDO:0002601
nasal cavity and paranasal sinus lethal midline granuloma3MONDO:0006828MONDO:0019472
Hodgkins lymphoma2MONDO:0004952EFO:0000183
ovarian carcinoma2MONDO:0005140EFO:0001075
nasopharyngeal neoplasm2MONDO:0005375EFO:0004252
neoplasm of mature B-cells2MONDO:0004949EFO:0000096
germ cell tumor2MONDO:0005040EFO:0000514
mesothelioma2MONDO:0005065EFO:0000588
small cell lung carcinoma2MONDO:0008433EFO:0000702
peripheral neuropathy2MONDO:0005244EFO:0003100
tumor of uterus2MONDO:0021353EFO:0003859
breast neoplasm2MONDO:0021100EFO:0003869
upper aerodigestive tract neoplasm2MONDO:0005398EFO:0004284
head and neck cancer2MONDO:0005627EFO:0006859
transitional cell carcinoma2MONDO:0006474EFO:1000601
peritoneal neoplasm2MONDO:0006901EFO:1001100
carcinoid tumor2MONDO:0005369EFO:0004243
urothelial carcinoma2MONDO:0040679EFO:0008528
fallopian tube carcinoma2MONDO:0006206EFO:1000251
pancreatic endocrine carcinoma2MONDO:0005893EFO:0007416
central nervous system neoplasm2MONDO:0006130EFO:1000158
neuroendocrine neoplasm2MONDO:0019496EFO:1001901
anus neoplasm2MONDO:0003046MONDO:0001879
neuroendocrine carcinoma2MONDO:0002120MONDO:0002120
fallopian tube neoplasm2MONDO:0021092MONDO:0002158
ovarian cancer2MONDO:0008170MONDO:0008170
lung neoplasm2MONDO:0021117MONDO:0008903
endometrium neoplasm2MONDO:0021251MONDO:0011962
follicular lymphoma2MONDO:0018906MONDO:0018906
renal cell carcinoma2MONDO:0005086EFO:0000681
bile duct neoplasm2MONDO:0021662MONDO:0003059
bile duct carcinoma2MONDO:0005496EFO:0005540
hilar cholangiocarcinoma2MONDO:0003345EFO:1001959
peripheral T-cell lymphoma, not otherwise specified2MONDO:0004964EFO:0000211
nasopharyngeal carcinoma2MONDO:0015459MONDO:0015459
gliosarcoma1MONDO:0016681EFO:1001465
myelodysplastic syndrome1MONDO:0018881EFO:0000198
acute myeloid leukemia1MONDO:0018874EFO:0000222
cutaneous melanoma1MONDO:0005012EFO:0000389
leukemia1MONDO:0005059EFO:0000565
neuroblastoma1MONDO:0005072EFO:0000621
liver disorder1MONDO:0005154EFO:0001421
primary cutaneous T-cell non-Hodgkin lymphoma1MONDO:0000607EFO:0002913
hematopoietic and lymphoid system neoplasm1MONDO:0002334MONDO:0044881
metastatic melanoma1MONDO:0005191EFO:0002617
gastrointestinal stromal tumor1MONDO:0011719MONDO:0011719
triple-negative breast carcinoma1MONDO:0005494EFO:0005537
glioblastoma1MONDO:0018177MONDO:0020690

23 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 1,475.

Phase distribution

PhaseTrials
PHASE2796
PHASE3240
PHASE1182
PHASE1/PHASE2138
PHASE2/PHASE349
Not specified48
PHASE415
EARLY_PHASE17

Top trials by phase / activity

NCTPhaseStatusTitle
NCT05498766PHASE4NOT_YET_RECRUITINGEffect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients
NCT07094893PHASE4NOT_YET_RECRUITINGAnti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status
NCT00129870PHASE4TERMINATEDCONCEPT: Comparison of Oxaliplatin vs Conventional Methods With Calcium/Magnesium in First-Line Metastatic Colorectal Cancer
NCT00263055PHASE4COMPLETEDMASCOT : Multicenter Asia Study in Adjuvant Treatment of Colon Cancer With OxaliplaTin/5FU-LV
NCT00274885PHASE4UNKNOWNRelationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer
NCT00559676PHASE4COMPLETEDStudy of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer
NCT00577031PHASE4COMPLETEDOBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum.
NCT01023633PHASE4UNKNOWNOPTIMOX1 in Chinese mCRC Patients
NCT01588990PHASE4COMPLETEDA Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer
NCT01959061PHASE4UNKNOWNEfficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases
NCT01972503PHASE4UNKNOWNIntraoperative Intraportal Chemotherapy Combined With Adjuvant Chemotherapy for Stage II and III Colorectal Cancer
NCT02366819PHASE4SUSPENDEDGenetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
NCT02557490PHASE4UNKNOWNOxaliplatin and Raltitrexed Treatment of Colorectal Cancer With Liver Metastases
NCT02557503PHASE4UNKNOWNHepatic Arterial Infusion of Oxaliplatin and Fluorouracil Treatment of Advanced Primary Liver Cancer After TACE
NCT02582970PHASE4COMPLETEDA Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum
NCT00217737PHASE3ACTIVE_NOT_RECRUITINGOxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
NCT01081262PHASE3ACTIVE_NOT_RECRUITINGCarboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer
NCT01918527PHASE3ACTIVE_NOT_RECRUITINGNeoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon Cancer
NCT01924819PHASE2/PHASE3ACTIVE_NOT_RECRUITINGTrial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma
NCT01935778PHASE3RECRUITINGCompare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer at Stage IIIb and IV(KCSG ST15-08): TRIUMPH
NCT02509286PHASE3ACTIVE_NOT_RECRUITINGPerioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus
NCT02885753PHASE3RECRUITINGSystemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
NCT02912559PHASE3ACTIVE_NOT_RECRUITINGCombination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
NCT02919787PHASE2/PHASE3ACTIVE_NOT_RECRUITINGNordic Pancreatic Cancer Trial (NorPACT) - 1
NCT02997228PHASE3ACTIVE_NOT_RECRUITINGTesting the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study
NCT03017326PHASE3ACTIVE_NOT_RECRUITINGPaediatric Hepatic International Tumour Trial
NCT03399110PHASE3ACTIVE_NOT_RECRUITINGXELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)
NCT03478488PHASE3ACTIVE_NOT_RECRUITINGProgrammed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC
NCT03504397PHASE3ACTIVE_NOT_RECRUITINGA Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
NCT03533582PHASE3ACTIVE_NOT_RECRUITINGCisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
NCT03653507PHASE3ACTIVE_NOT_RECRUITINGA Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
NCT03801876PHASE3RECRUITINGComparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
NCT03961841PHASE3NOT_YET_RECRUITINGPerioperative Combination Chemotherapy Versus Chemoradiation for Locally Advanced EGJ Adenocarcinoma
NCT04008030PHASE3ACTIVE_NOT_RECRUITINGA Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator’s Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
NCT04068103PHASE2/PHASE3ACTIVE_NOT_RECRUITINGCirculating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
NCT04094688PHASE3ACTIVE_NOT_RECRUITINGVitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
NCT04137107PHASE2/PHASE3ACTIVE_NOT_RECRUITINGDuloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer
NCT04208347PHASE2/PHASE3ACTIVE_NOT_RECRUITINGPerioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer
NCT04210115PHASE3ACTIVE_NOT_RECRUITINGStudy of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
NCT04246684PHASE3ACTIVE_NOT_RECRUITINGShort RT Versus RCT,Followed by Chemo.and Organ Preservation for Interm and High-risk Rectal Cancer Patients
NCT04248452PHASE3ACTIVE_NOT_RECRUITINGTesting the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body
NCT04340141PHASE3ACTIVE_NOT_RECRUITINGTesting the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
NCT04365036PHASE3RECRUITINGA Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)
NCT04375605PHASE3ACTIVE_NOT_RECRUITINGNeoadjuvant RCT Versus CT for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the GEJ
NCT04384484PHASE3ACTIVE_NOT_RECRUITINGStudy to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT04408638PHASE3ACTIVE_NOT_RECRUITINGA Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT04447352PHASE3RECRUITINGHIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT)
NCT04460352PHASE3RECRUITINGChemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer
NCT04607421PHASE3ACTIVE_NOT_RECRUITINGA Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
NCT04787354PHASE3RECRUITINGOptimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX)
NCT04854668PHASE3ACTIVE_NOT_RECRUITINGA Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer
NCT04861558PHASE3RECRUITINGEfficacy of Hyperthermic Intraperitoneal Chemotherapy
NCT04927780PHASE3ACTIVE_NOT_RECRUITINGPerioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
NCT04949256PHASE3ACTIVE_NOT_RECRUITINGEfficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)
NCT04997837PHASE3RECRUITINGStudy of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma
NCT05139017PHASE2/PHASE3RECRUITINGA Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
NCT05144854PHASE3ACTIVE_NOT_RECRUITINGA Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
NCT05152147PHASE3ACTIVE_NOT_RECRUITINGA Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
NCT05171647PHASE3ACTIVE_NOT_RECRUITINGA Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma
NCT05171660PHASE3ACTIVE_NOT_RECRUITINGCombination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer
NCT05236972PHASE3RECRUITINGPACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer
NCT05239741PHASE3ACTIVE_NOT_RECRUITINGStudy of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)
NCT05253651PHASE3RECRUITINGA Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
NCT05264896PHASE3RECRUITINGPerioperative FLOT vs Adjuvant XELOX for CA Stomach
NCT05314998PHASE3NOT_YET_RECRUITINGAdjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature
NCT05342194PHASE3RECRUITINGToripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study
NCT05568095PHASE3ACTIVE_NOT_RECRUITINGA Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
NCT05677490PHASE3RECRUITINGmFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
NCT05699655PHASE2/PHASE3RECRUITINGTislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer
NCT05699746PHASE3NOT_YET_RECRUITINGCAPEOX vs Observation in Colorectal Cancer Patients With Positive MRD
NCT05700448PHASE3NOT_YET_RECRUITINGStudy of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma
NCT05771480PHASE3ACTIVE_NOT_RECRUITINGDurvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)
NCT05863195PHASE3RECRUITINGTesting Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
NCT05914610PHASE3NOT_YET_RECRUITINGEnvollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer
NCT05976568PHASE2/PHASE3NOT_YET_RECRUITINGA Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
NCT06017583PHASE3RECRUITINGNeoadjuvant Chemotherapy With PD-1 Inhibitors Combined With SIB-IMRT in the Treatment of Locally Advanced Rectal Cancer
NCT06028737PHASE2/PHASE3RECRUITINGTotal Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer
NCT06041477PHASE3RECRUITINGConcurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
NCT06177041PHASE3RECRUITINGM108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
NCT06205485PHASE3RECRUITINGNeoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
NCT06206733PHASE3ACTIVE_NOT_RECRUITINGASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma
NCT06279130PHASE2/PHASE3RECRUITINGPan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations
NCT06280495PHASE2/PHASE3RECRUITINGNeoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
NCT06441565PHASE2/PHASE3RECRUITINGFruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer
NCT06490536PHASE3RECRUITINGThe Sagittarius Trial
NCT06507371PHASE3RECRUITINGNode-sparing Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Rectal Cancer
NCT06508658PHASE3ACTIVE_NOT_RECRUITINGA Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT06521255PHASE3RECRUITINGEvaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT06532006PHASE3RECRUITINGA Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
NCT06571461PHASE3NOT_YET_RECRUITINGLiposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer
NCT06625320PHASE3ACTIVE_NOT_RECRUITINGPhase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
NCT06662786PHASE3RECRUITINGA Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662877PHASE2/PHASE3NOT_YET_RECRUITINGAnlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment
NCT06733038PHASE3RECRUITINGFOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.
NCT06764875PHASE3RECRUITINGA Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
NCT06792253PHASE3RECRUITINGStudy Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT06793917PHASE3RECRUITINGTislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
NCT06841679PHASE2/PHASE3RECRUITINGUtidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
NCT06897644PHASE3RECRUITINGGemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.
NCT06901531PHASE3RECRUITINGA Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

Clinical evidence (CIViC)

Variant × indication × effect (19 predictive associations from 19 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
BRCA1 MutationPancreatic CancerSensitivity/ResponseCisplatin + OxaliplatinCIViC BEID5915
HSPH1 T17 DELETIONColorectal CancerSensitivity/ResponseFluorouracil + OxaliplatinCIViC BEID1164
TP53 WildtypeColorectal CancerSensitivity/ResponseCapecitabine + Oxaliplatin + CetuximabCIViC BEID875
BRAF D594KColorectal CancerResistanceOxaliplatinCIViC BEID6403
BRAF MutationColorectal CancerResistanceOxaliplatinCIViC BEID6303
BRAF V600EColorectal CancerResistanceOxaliplatinCIViC BEID2117
BRAF V600EColorectal CancerResistanceBevacizumab + Capecitabine + OxaliplatinCIViC BEID2121
BRAF V600EColorectal CancerResistanceOxaliplatin + Capecitabine + Bevacizumab + CetuximabCIViC BEID8646
DKK1 NUCLEAR EXPRESSIONColorectal CancerResistanceLevoleucovorin + Oxaliplatin + Fluorouracil + IrinotecanCIViC BEID824
ERBB2 AmplificationColorectal CancerResistanceOxaliplatin + Cetuximab + CapecitabineCIViC BEID895
KRAS G12/G13Colorectal CancerResistanceOxaliplatinCIViC BEID6293
MLH1 METHYLATIONStomach CarcinomaResistanceOxaliplatinCIViC BEID1315
PIK3CA MutationColorectal CancerResistanceOxaliplatinCIViC BEID6298
PIK3CA E81KColorectal CancerResistanceCetuximab + Fluorouracil + OxaliplatinCIViC CEID4464
PIK3CA R93WColorectal CancerResistanceOxaliplatin + Cetuximab + FluorouracilCIViC CEID4467
MSH3 K383fsColon CarcinomaSensitivity/ResponseOxaliplatin + 7-Ethyl-10-HydroxycamptothecinCIViC DEID9089
FOXC2 OverexpressionColorectal CancerResistanceOxaliplatinCIViC DEID8084
POU5F1 EXPRESSIONColon CancerResistanceOxaliplatinCIViC DEID958
ZEB1 ExpressionColon CancerResistanceOxaliplatinCIViC DEID8086

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.4
BioBTree
v2.0.2

Sources 15

This page pulls from 15 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclinical_trialsefogtopdb_interactiongtopdb_ligandmeshmondopatent_compoundpharmgkbpharmgkb_guidelinepubchem